Harbour BioMed (Guangzhou) Co. Ltd.
14
0
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
21%
3 trials in Phase 3/4
11%
1 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Trial of HBM9378 in Healthy Chinese Subjects
Role: lead
A Study Evaluating HBM9036 Efficacy and Safety on Moderate to Severe Dry Eye
Role: lead
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
Role: lead
A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP
Role: lead
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
Role: lead
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
Role: lead
A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients
Role: lead
A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease
Role: lead
A Study of HBM9161 in NMOSD Patients
Role: lead
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors
Role: lead
A Study Evaluating the Efficacy and Safety on Moderate to Severe Dry Eye
Role: lead
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody
Role: lead
A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers
Role: lead
Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab
Role: lead
All 14 trials loaded